DEF: Bone Biologics Postpones Annual Meeting, Proposes Reverse Stock Split

Bone Biologics Corporation has rescheduled its Annual Meeting of Stockholders to September 28, 2026, adding proposals for warrant share issuance approval and a reverse stock split.

Summary

• Bone Biologics Corporation has postponed its Annual Meeting of Stockholders from August 11, 2026, to September 28, 2026.
• The meeting will now include new proposals: approving the potential issuance of shares underlying certain warrants (Proposal Four), approving an amendment to the charter for a reverse stock split (Proposal Five), and approving an adjournment if necessary (Proposal Six).
• The company is seeking stockholder approval for the issuance of shares underlying warrants issued in a private placement on July 7, 2026, which could exceed 20% of outstanding shares and is required by Nasdaq Listing Rule 5635(d).
• A reverse stock split, in a range of 1-for-2 to 1-for-10, is proposed to maintain compliance with Nasdaq listing requirements, as the current stock price is below $1.00.
• The Board of Directors recommends voting FOR all proposals, including the election of four directors, advisory vote on executive compensation, ratification of the independent auditor, and the new proposals.
• The record date for determining stockholders entitled to vote is August 6, 2026, with 2,011,057 shares of common stock outstanding.
• The company's 2025 Annual Report, including its Form 10-K, will be made available to stockholders around August 28, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the proposed reverse stock split, which is often a sign of financial distress, and the need to seek stockholder approval for warrant issuances, indicating potential dilution.

Positives

• The company is proactively addressing potential Nasdaq delisting by proposing a reverse stock split.
• The Board of Directors is seeking stockholder approval for key corporate actions, demonstrating a commitment to governance.
• The company has a clear process for stockholder communication and voting, including internet and telephone options.
• The independent auditor, Weinberg & Company, P.A., is being presented for ratification, indicating a standard governance practice.

Negatives

• The need for a reverse stock split suggests the company's stock price is significantly depressed, potentially indicating underlying business challenges.
• The company is seeking approval for the issuance of shares underlying warrants, which will result in dilution for existing shareholders.
• The company has already completed a private placement and issued warrants, with stockholder approval now being sought for the share issuance related to these warrants.
• The company's stock price was $0.93 as of the record date, below the $1.00 threshold for Nasdaq compliance.
• The company has experienced significant net losses in recent years ($3,108,991 in 2025, $4,112,420 in 2024, $8,948,731 in 2023).

Risks

• Failure to approve the reverse stock split could lead to delisting from the Nasdaq Capital Market.
• The potential issuance of shares underlying warrants could significantly dilute existing shareholders' ownership.
• The company's ability to fund its operations could be jeopardized if the potential proceeds from warrant exercises are not realized due to lack of stockholder approval.
• The reverse stock split may not achieve its intended effects of increasing the stock price or marketability, and could even lead to a further decline in stock price.
• The company has a history of reverse stock splits, and the stock price did not remain elevated for an extended period after previous splits.
• The company is in the development stage and is pre-revenue, indicating inherent risks associated with bringing a medical device to market.

Future Outlook

The company is seeking stockholder approval for a reverse stock split to maintain its Nasdaq listing and for the issuance of shares underlying warrants from a recent private placement. The success of these proposals is critical for continued Nasdaq compliance and potential future funding.

Management Comments

• Stockholders are urged to vote promptly, whether by internet, telephone, or mail, to ensure their shares are represented at the Annual Meeting.
• The Board believes that effecting the Reverse Stock Split would help the company maintain its listing on the Nasdaq Capital Market, increase the per share price of its Common Stock, and maintain the marketability and liquidity of its Common Stock.
• The Board unanimously recommends that stockholders vote FOR each of the four director nominees and FOR Proposals Two, Three, Four, Five and Six.

Industry Context

StockSavvy.ai notes that the proposed reverse stock split is a common, albeit often viewed negatively, tactic for companies struggling to maintain minimum bid price requirements on exchanges like Nasdaq. The need to seek stockholder approval for warrant issuance also highlights potential dilution concerns prevalent in development-stage biotech companies seeking capital.

Comparison to Industry Standards

• The proposed reverse stock split ratio (1-for-2 to 1-for-10) is within the typical range for companies aiming to boost their stock price to meet exchange listing requirements.
• The company's net losses are substantial, which is not uncommon for pre-revenue biotechnology firms, but the magnitude and trend are important considerations.
• The executive compensation structure, with base salary, performance-based cash awards, and stock options, aligns with standard practices for smaller public companies, though the absolute amounts are modest.
• The company's reliance on private placements and warrants for capital raises is a common strategy for early-stage companies, but it carries inherent dilution risks.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that, if determined adversely, would have a material adverse effect on its business, results of operations, financial condition, or cash flows.

Related Party Transactions

• No related party transactions are disclosed as having occurred since January 1, 2024, where any director, officer, significant stockholder, or their relatives had a material direct or indirect interest.

Stakeholder Impact

• Shareholders will experience dilution if warrants are exercised and may see their per-share ownership decrease if a reverse stock split is implemented.
• Shareholders face the risk of delisting from Nasdaq if the reverse stock split is not approved or does not effectively increase the stock price.
• The potential capital raise from warrant exercises could provide necessary funding for operations and business development, benefiting long-term stakeholders if successful.
• The reverse stock split aims to improve marketability and liquidity, potentially benefiting all shareholders by attracting a broader investor base.

Next Steps

• Stockholders will vote on six proposals at the rescheduled Annual Meeting on September 28, 2026.
• If approved, the Board of Directors will decide whether and at what ratio (1-for-2 to 1-for-10) to implement the reverse stock split, with the effective date being no later than one year after the Annual Meeting.
• The company will file a Form 8-K with the SEC within four business days after the Annual Meeting to report the voting results.

Key Dates

Recommendation

The company faces significant challenges, including a depressed stock price requiring a reverse stock split and potential dilution from warrant exercises. While the company is taking steps to address these issues and maintain its Nasdaq listing, the inherent risks of a pre-revenue biotech firm and the negative perception often associated with reverse stock splits warrant a cautious 'hold' stance. Further clarity on the success of the reverse stock split and the company's path to revenue generation would be needed for a more positive outlook.

Keywords

Bone Biologics, Annual Meeting, Proxy Statement, Reverse Stock Split, Warrants, Nasdaq Listing, Stockholder Approval, Executive Compensation